BeiGene's (HKG:6160, SHA:688235) loss narrowed to $151.9 million in the fourth quarter of 2024 from $367.6 million in the year-ago period.
Loss per share at the drug company narrowed to $0.11 from $0.27 in the previous year, according to a Thursday filing with the Hong Kong bourse.
Total revenue surged to $1.12 billion from $630.5 million a year earlier.
For 2025, full-year revenue is seen to range between $4.9 billion and $5.3 billion. It also forecasts positive GAAP operating income, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。